DE60018422D1 - Typ v pde-hemmer zur behandlung von mukoviszidose - Google Patents

Typ v pde-hemmer zur behandlung von mukoviszidose

Info

Publication number
DE60018422D1
DE60018422D1 DE60018422T DE60018422T DE60018422D1 DE 60018422 D1 DE60018422 D1 DE 60018422D1 DE 60018422 T DE60018422 T DE 60018422T DE 60018422 T DE60018422 T DE 60018422T DE 60018422 D1 DE60018422 D1 DE 60018422D1
Authority
DE
Germany
Prior art keywords
treatment
type
mucoviscidosis
hemmer
pde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60018422T
Other languages
English (en)
Other versions
DE60018422T2 (de
Inventor
Robert Leslie Dormer
Margaret Ann Mcpherson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Cardiff University
Original Assignee
University College Cardiff Consultants Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd, Cardiff University filed Critical University College Cardiff Consultants Ltd
Application granted granted Critical
Publication of DE60018422D1 publication Critical patent/DE60018422D1/de
Publication of DE60018422T2 publication Critical patent/DE60018422T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60018422T 1999-04-22 2000-04-20 Typ v pde-hemmer zur behandlung von mukoviszidose Expired - Fee Related DE60018422T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9909135.7A GB9909135D0 (en) 1999-04-22 1999-04-22 Cystic fibrosis medicaments
GB9909135 1999-04-22
PCT/GB2000/001564 WO2000064424A2 (en) 1999-04-22 2000-04-20 Cystic fibrosis medicaments

Publications (2)

Publication Number Publication Date
DE60018422D1 true DE60018422D1 (de) 2005-04-07
DE60018422T2 DE60018422T2 (de) 2006-04-06

Family

ID=10851966

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60018422T Expired - Fee Related DE60018422T2 (de) 1999-04-22 2000-04-20 Typ v pde-hemmer zur behandlung von mukoviszidose

Country Status (7)

Country Link
US (2) US6599907B1 (de)
EP (1) EP1194148B1 (de)
AT (1) ATE289813T1 (de)
AU (1) AU4133400A (de)
DE (1) DE60018422T2 (de)
GB (1) GB9909135D0 (de)
WO (1) WO2000064424A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
DE602004022819D1 (de) * 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US7101289B2 (en) * 2004-10-07 2006-09-05 Callaway Golf Company Golf club head with variable face thickness
US8012041B2 (en) * 2004-10-07 2011-09-06 Callaway Golf Company Golf club head with variable face thickness
ATE533749T1 (de) * 2005-05-24 2011-12-15 Vertex Pharma Modulatoren von atp-bindenden kassettentransportern
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
US7753809B2 (en) * 2007-12-19 2010-07-13 Cackett Matthew T Driver with deep AFT cavity
MX2013002895A (es) * 2010-09-14 2013-06-05 Inst Biochemii I Biofizyki Pan Compuestos como moduladores de una proteina cftr mutante y su uso para tratar enfermedades asociadas con las deficiencias de la proteina cftr.
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
AU2015340215B2 (en) * 2014-10-29 2018-11-15 Dong-A St Co., Ltd Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728705A (en) 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis

Also Published As

Publication number Publication date
US6599907B1 (en) 2003-07-29
AU4133400A (en) 2000-11-10
WO2000064424A3 (en) 2001-06-07
US6936618B2 (en) 2005-08-30
GB9909135D0 (en) 1999-06-16
EP1194148B1 (de) 2005-03-02
WO2000064424A8 (en) 2001-10-18
DE60018422T2 (de) 2006-04-06
ATE289813T1 (de) 2005-03-15
US20030229117A1 (en) 2003-12-11
WO2000064424A2 (en) 2000-11-02
EP1194148A2 (de) 2002-04-10

Similar Documents

Publication Publication Date Title
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
UY27175A1 (es) Nueva sal succinato de o-desmetil- venlafaxina
ATE312202T1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
DE60042984D1 (de) Arzneitmittel zur Behandlung von Duchenne-Muskeldystrophie
TW200510375A (en) New compounds
ATE381539T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
ATE358669T1 (de) Pyrazolderivate zur behandlung von hiv
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60132600D1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60018422D1 (de) Typ v pde-hemmer zur behandlung von mukoviszidose
AR032293A1 (es) Estuche farmaceutico
MXPA03002911A (es) Compuestos quimicos.
AU2001266575A1 (en) Chemical compounds
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
SE9802208D0 (sv) Novel compounds
SE9902765D0 (sv) Novel compounds
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee